Diagnos $ADK #DGNOF Signs Memorandum of Understanding with #Essilor International

Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of critical health issues, is pleased to announce that it has entered into a Memorandum of Understanding (MoU) with the Instruments division of Essilor International, a subsidiary of EssilorLuxottica. Essilor International is the world’s leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses and diagnostic ophthalmic instruments.

 The MoU is non-binding and forms the basis of a potential distribution agreement with Essilor International for DIAGNOS’ CARA platform for the AI-enhanced analysis of wide-field retinal images, as well as of certain specified future developments of the CARA platform for a variety of applications.

 DIAGNOS has under development multiple new applications involving AI-enhanced retinal imaging to address a growing need for general purpose pathology identification. In addition to localized retinal pathology, such as macular degeneration and glaucoma, certain retinal pathologies are also known indicators of various systemic disorders, including cardiovascular and diabetic diseases. On July 20th 2021, DIAGNOS announced a clinical trial with CommonSpirit Health Research Institute in the USA for the early detection of stroke through the inspection and analysis of the retina.

 “DIAGNOS is focused on its commercialization strategy and pursuing opportunities with potential partners. We are very pleased that our AI-based technology has attracted the attention of global eyecare sector leaders such as Essilor International and we are looking forward to our discussions with respect to a mutually beneficial potential worldwide distribution agreement. At the same time, DIAGNOS continues to invest in Research and Development, furthering the creation of our intellectual property by partnering with Quebec government programs and local university (École de Technologie Supérieure) to ensure that we stay ahead of our competition worldwide,” said Mr. André Larente, President of DIAGNOS

Diagnos $ADK $DGNOF Announces the Opening of the #AI Assisted #Screening #Clinic at #Magrabi #Hospital with the Presence of the Undersecretary of the Ministry of #Health of #SaudiArabia

Diagnos Inc. (“DIAGNOS” or the “Company”) (TSX Venture: ADK) (OTCQB: DGNOF) (FRA: 4D4A), a leader in early detection of critical health issues, is pleased to announce the official opening of the initial clinics at the Magrabi Hospital.

Dr. Ibrahim Al-Omar, Undersecretary of the Ministry of Health for Investment, inaugurated last Wednesday the early detection unit for diabetic retinopathy operated by DIAGNOS’ AI (Artificial Intelligence) technology at Magrabi Eye, Ear and Dental Hospital in Riyadh, the first of its kind in the Kingdom. The inauguration was attended by the executive management of the Magrabi Group represented by Mr. Mutasim Alireza, Managing Director, Dr. Tariq Al-Hamad, Regional Operations Director, Senior Retinal Consultants, Yves-Stephane Couture, Vice President of DIAGNOS and members of the management of Kanhoor Company and Bayer Pharmaceuticals.

When asked, Dr. Walid bin Abdul Rahman Al-Turki, head of the retinal departments at Magrabi Group in Riyadh, stated that the aim of this unit is to examine the largest possible number of diabetic patients who are at risk of developing retinal diseases associated with them, which unfortunately may end in a gradual complete loss of vision. It is known that the incidence of diabetes in the Kingdom is about 27% of the population, which indicates the extent of the potential risk. At the conclusion of the interview, Dr. Walid Al-Turki stated that the initiative is in its infancy, and the Magrabi Group will develop and circulate it in all branches upon completion of its review.

Magrabi Hospitals and Centers has thirty-four branches in the Middle East; Twenty-two of them are in the Kingdom in Riyadh, Jeddah, Makkah, Dammam, Khobar, Al-Ahsa, Jubail, Asir, Jazan, Madinah, and Qassim.  Magrabi Hospitals and Centers Group was established in Jeddah in 1955 as the first hospital specialized in ophthalmology, and today it is the largest specialized medical network in the region.

The event was reported by the SABQ online newspaper (sabq.org) and the link is attached:

https://mobile.sabq.org/gJxtfn

Magrabi Hospitals launches initiative for early screening for diabetic retinopathy

“We extend our best wishes to Magrabi hospitals.  We would also like to thank everyone in attendance for their time and efforts in making this project a reality. The main beneficiaries will be many thousands of diabetic patients whose vision can now be protected through this collaboration,” said André Larente, President of DIAGNOS.

Diagnos Inc. $ADK $DGNOF #Interview with InvestorIntel – #AI #Healthcare #Technology for #Diabetic #BlindnessPrevention

Diagnos $ADK $DGNOF Enters into Exclusive Distribution Agreement to Access Massive Global Healthcare Market in DACH Countries and Central Europe of Over 140 Million People

Diagnos Inc. TSXV-ADK OTCQB: DGNOF a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today the signing of an exclusive distribution agreement with Diagnos Europe GmbH (“Diagnos Europe”), a new partner for DIAGNOS to tackle the strategically important DACH countries in the European market (Germany, Austria, Switzerland) and the surrounding countries Poland, Luxembourg and Liechtenstein in order to prepare a successful market entry for the Company’s products and services in Central Europe, a crucial territory for DIAGNOS with a significant market potential in access of more than 140 million people.

DACH is an abbreviation and D stands for Deutschland (Germany), A, Austria, and CH, Confoederatio Helvetica, (Switzerland). Therefore, it refers to the mostly German-speaking center of Europe. The DACH economy is one of the most stable in the entire world since the end of World War II and it is by far the largest and most promising market for IT and AI in Europe. Diagnos Europe is fully specialized on go-to-market strategies and services in the DACH countries and have developed for DIAGNOS a variety of market entry strategies offering the Company a practical and effective launch pad into the DACH market. 

 Just as the DACH region has become established as Europe’s most important region for the optical market, DIAGNOS will be benefiting from the forthcoming market entry developments and has in addition that long tapping into European potential. The German market, in particular, plays a leading role in the optical industry and thus also for the Company and Diagnos Europe in terms of preparing the implementation of specific sales activities. Alongside the French market, which DIAGNOS is also targeting at the same time, the German-speaking market is the most important in Europe and also the most interesting for the company as a result of its stable growth rates over the past several years. For 2019, the German optical industry was able to record its most successful financial year in a decade, far outperforming other European markets (total sales compared to 2018 were up by 5.4% at EUR 4.7 billion; 2019 thus exceeding all expectations and a continuation of the growth trend that has persisted since 2011. Opticians and optometrists have continuously been able to look forward to a further increase in turnover, which rose to almost EUR 6.5 billion in 2019 and even more in 2020).

Read more:  http://www.diagnos.ca/wp-content/uploads/2021/04/DIAGNOS-Enters-into-Exclusive-Distribution-Agreement-to-Access-Massive-Global-Healthcare-Market-in-DACH-Countries.pdf